Drug Type Small molecule drug |
Synonyms Front-loaded + [5] |
Target |
Action blockers |
Mechanism H+/K+ ATPase blockers(Potassium-transporting ATPase blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H26N4O2 |
InChIKeyGHVIMBCFLRTFHI-UHFFFAOYSA-N |
CAS Registry248919-64-4 |
Start Date27 Nov 2022 |
Sponsor / Collaborator |
Start Date15 Nov 2022 |
Sponsor / Collaborator |
Start Date13 Jul 2022 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroesophageal Reflux | Phase 1 | Canada | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | Denmark | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | United Kingdom | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | France | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | Sweden | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | Germany | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | United States | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | Italy | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | Finland | 01 May 2004 | |
Gastroesophageal Reflux | Phase 1 | Norway | 01 May 2004 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 35 | Linaprazan glurate+Clarithromycin (Part I) | ysboqfaels(odxvakjjsh) = gdsqmkhsbu cmlactvzws (qjzwcyydqx, gjmnyhyruv - isrvmbhiac) View more | - | 03 Jan 2025 | ||
Linaprazan glurate hydrochloride (HCl)+Midazolam (Part II) | giossaamgt(lcqxhmkjov) = doegxllxwl qehdgetngr (yuxuouacfv, niloztnqwh - xdrhadlgpl) View more |